Funnel plot for PMI incidence to rule out publication bias.

<p>Funnel plot was generated using a fixed-effect model by Review Manager 5.2.0.</p

Characteristics of included studies.

<p>PCI = percutaneous coronary intervention; CK-MB = creatine kinase-MB; UNL = upper normal limit of normal; NSTE-ACS = non-ST-segment elevation acute coronary syndrome;</p><p>Characteristics of included studies.</p

Forest plots for PMI incidence for patients stratified by different clinical presentation.

<p>Forest plots were generated using Review Manager 5.2.0 for patients with stable angina, ACS or mixed disease presentation from individual and pooled trials. The incidence of PMI was expressed as a dichotomous variable, and the results were expressed as odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity across trials was evaluated with I² statistic, defined as I²>50%. Because the heterogeneity was low, a fixed-effect model was used.</p

Funnel plot for PMI incidence for statin naïve patients.

<p>Forest plot was generated using Review Manager 5.2.0 for statin naïve patients from individual and pooled trials. The incidence of PMI was expressed as a dichotomous variable, and the results were expressed as odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity across trials was evaluated with I² statistic, defined as I²>50%. Because the heterogeneity was low, a fixed-effect model was used.</p

Funnel plot for MACE incidence to rule out publication bias.

<p>Funnel plot was generated using a fixed-effect model by Review Manager 5.2.0.</p

Clinical events in follow-up.

<p>Spontaneous MI = spontaneous myocardial infarction; ACS = acute coronary syndrome;</p><p>TVR = target vessel revascularization; MACE = major adverse cardiovascular events;</p><p>NA = not available.</p><p>Clinical events in follow-up.</p

Characteristics of included studies.

<p>PCI = percutaneous coronary intervention; CK-MB = creatine kinase-MB; UNL = upper normal limit of normal; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; ROMA trial = Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of periprocedural myocardial necrosis; ROMA II trial = Comparison of high reloading Rosuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of periprocedural myocardial necrosis; NA = not available.</p><p>Characteristics of included studies.</p

Funnel plot for PMI incidence for patients with prior low-dose statin use.

<p>Forest plot was generated using Review Manager 5.2.0 for patients with prior low-dose statin use from individual and pooled trials. The incidence of PMI was expressed as a dichotomous variable, and the results were expressed as odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity across trials was evaluated with I² statistic, defined as I²>50%. A random-effect model was used for the subgroup with prior low-dose statin treatment because heterogeneity existed for this group.</p

Quality of included RCTs.

<p>NA = not available.</p><p>Quality of included RCTs.</p